EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Randomisierte kontrollierte StudieOpen Access

Liraglutide and Weight Loss Among Suboptimal Responders to Metabolic Bariatric Surgery

Wendy A Brown, Paul R Burton, Cheryl Laurie, Eldho Paul, Yazmin Johari, Michael A Cowley, John Wentworth

JAMA Network Open · 29.10.2025 · 8 (10) · e2539848

DOI: 10.1001/jamanetworkopen.2025.39848 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift JAMA Network Open, online erschienen am 29.10.2025. Verfasst von Wendy A Brown und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Bariatric Surgery, Liraglutide, Obesity, Morbid, Weight Loss. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Suboptimal weight loss after metabolic bariatric surgery (MBS) is a common indication for conversion surgery. The use of obesity management medications may improve weight loss, reducing the need for further surgery.

Objective

To examine whether liraglutide improves weight loss and health outcomes after MBS in patients who have had suboptimal weight loss. Design, Setting, and Participants This prospective, double-blinded, single-center randomized clinical trial compared the effect of daily liraglutide with placebo in adults treated at an academic surgical department. Patients with anatomically correct adjustable gastric band, sleeve gastrectomy, one anastomosis gastric bypass, or Roux-en-Y gastric bypass (confirmed with barium swallow and/or endoscopy) were invited to participate at 12 to 36 months after surgery if they had a body mass index greater than 35 (calculated as weight in kilograms divided by height in meters squared), were aged 20 to 65 years, and had achieved a stable weight (defined as a weight consistently within a 4-kg range during a 3-month period) with an excess body weight loss (defined using body mass index threshold of 25) of 25% to 40% or total body weight loss of 5% to 12% for anatomically correct adjustable gastric band and excess body weight loss of 25% to 60% or total body weight loss of 10% to 20% for sleeve gastrectomy, Roux-en-Y gastric bypass, and one anastomosis gastric bypass. The first participant was randomized on January 18, 2019, and the last on June 9, 2023. Primary data analysis occurred on July 15, 2024.

Intervention

Study intervention was liraglutide or placebo self-administered daily by participants. Participants self-titrated dosing. Treatment was intended for 12 months. Main Outcomes and Measures Primary outcome was weight loss at 12 months. Change in health and quality of life were secondary measures.

Results

The study included 24 participants in each arm (liraglutide arm: mean [SD] age, 48.7 [10.5] years; 22 [92%] female; placebo arm: mean [SD] age, 43.6 [11.4] years; 20 [83%] female). In the liraglutide arm, 4 patients withdrew and 1 was lost to follow-up. In the placebo arm, 6 patients withdrew and 6 were lost to follow-up. At 12 months, mean (SE) weight loss in the liraglutide group was 5.7 (1.1) kg with a mean (SD) weight gain of 1.4 (1.2) kg in the placebo group (between-group difference, 7.1 kg [95% CI, 3.9-10.3 kg]; P < .001). There were no adverse effects on health or quality of life. Conclusions and Relevance In this randomized clinical trial, liraglutide provided greater weight loss at 12 months than placebo in a cohort of patients with a suboptimal response to MBS. These results suggest that combining obesity management medications with MBS affords the opportunity to increase weight loss for those with a suboptimal initial response or weight regain, potentially avoiding conversion surgery. Trial Registration anzctr.org.au Identifier: ACTRN12617001613392

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bariatric SurgeryLiraglutideObesity, MorbidWeight LossAdultFemaleHumansMaleMiddle AgedBody Mass IndexDouble-Blind MethodProspective StudiesTreatment Outcome

Substanzen

Liraglutide

Autor:innen und Institutionen

  • Department of Surgery, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.
  • Oesophago-Gastric and Bariatric Unit, Alfred Health, Melbourne, Victoria, Australia.
  • Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
  • Department of Physiology, Monash University, Melbourne, Victoria, Australia.
  • Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Parkville, Victoria, Australia.

Zitieren

APA

Brown, W. A., Burton, P. R., Laurie, C., Paul, E., Johari, Y., Cowley, M. A., & Wentworth, J. (2025). Liraglutide and Weight Loss Among Suboptimal Responders to Metabolic Bariatric Surgery. JAMA Network Open, 8(10), e2539848. https://doi.org/10.1001/jamanetworkopen.2025.39848

Vancouver

Brown WA, Burton PR, Laurie C, Paul E, Johari Y, Cowley MA, et al. Liraglutide and Weight Loss Among Suboptimal Responders to Metabolic Bariatric Surgery. JAMA Network Open. 2025;8(10):e2539848. doi:10.1001/jamanetworkopen.2025.39848

BibTeX
@article{Brown2025,
  author = {Brown, Wendy A and Burton, Paul R and Laurie, Cheryl and Paul, Eldho and Johari, Yazmin and Cowley, Michael A and Wentworth, John},
  title = {Liraglutide and Weight Loss Among Suboptimal Responders to Metabolic Bariatric Surgery},
  journal = {JAMA Network Open},
  year = {2025},
  volume = {8},
  number = {10},
  pages = {e2539848},
  doi = {10.1001/jamanetworkopen.2025.39848}
}
Kostenlos starten →